Vivos Therapeutics stock falls 6% on second quarter revenue miss

Vivos Therapeutics Inc. (VVOS) reported disappointing second quarter results on Monday, missing revenue projections and causing a 6.5% drop in its stock price during pre-market trading. The medical device company generated $5.15 million in revenue for the quarter, falling short of the analyst consensus of $5.57 million. Despite this, Vivos posted an adjusted loss per share of -$0.31, surpassing the estimated -$0.37.

The surge in revenue, up 35% year-over-year, was primarily attributed to increased service revenue from sleep testing and treatment services in their Nevada operations. For the full six months ending June 30, 2026, revenue reached $10.3 million, a 51% increase from $6.8 million in the same period last year. Gross margin improved to 57% in the second quarter, up from 55% a year earlier.

However, operating loss remained stagnant at $4.9 million compared to the same period in 2025. With $1.8 million in cash and cash equivalents as of June 30, 2026, the company faced a $3.8 million deficit in stockholders' equity, up from a $1.5 million deficit at year-end 2025. Vivos did not disclose financial guidance for upcoming quarters.